News for Healthier Living

AACR: First-in-Class Covalent Werner Helicase Inhibitor Shows Clinical Proof-of-Concept in Phase I Trial

* RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors * Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors * This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies * Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

April 27, 2025


April 29 2025

April 28 2025

April 27 2025

April 26 2025

April 25 2025

April 24 2025

April 23 2025

April 22 2025

April 21 2025

April 19 2025

April 18 2025

April 17 2025

April 16 2025

April 15 2025